Onkologie. 2010:4(3):202-206

Anti-angiogenic therapy for metastatic colorectal cancer - analysis of date from two centers

Radka Obermannová¹, Tomáš Büchler², Michal Štícha³, Jiří Navrátil¹, Lenka Slamová¹, Jana Kaňáková², Jitka Abrahámová², Rostislav Vyzula¹

¹ Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

² Onkologické oddělení, Fakultní Thomayerova nemocnice a 1. lékařská fakulta Univerzity Karlovy, Praha

³ Institut biostatistiky a analýz, Masarykova univerzita, Brno

Background: The primary endpoint of this retrospective analysis was PFS, OS and RR in the group of the patients treated with the first

line chemotherapy and bevacizumab. As secondary endopoint we also analysed a treatment toxicity and selected prognostic a and

predictive factors.

Patients and methods: We analysed data from AVASTIN register completed with a clinical and laboratory informations. In relation with

results we analysed: age,, number of metastatic sites, KRAS status and hypertension.

Results: Two hundert two pts were treated with chemotherapy and bevacizumab. The median follow up was 9,7months. The median

progression-free was 11,3 months, median overall survival 30,6 months. Arterial hypertension didn´t correlate with the clinical outcome…

The main adverse events were hypertension and thromboembolic events.

Conclusions: Bevacizumab is a common part of the first line treatment of patients with mCRC in the Czech Republic. It should be the

main point of interest to find the predictive factors of efficasy because of the high treatment expenses.

Keywords: colorectal cancer, bevacizumab, prognostic factors

Published: July 1, 2010  Show citation